Carazolol
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATCvet code | QC07AA90 (WHO) |
Identifiers | |
|
|
CAS Number | 57775-29-8 |
PubChem (CID) | 71739 |
IUPHAR/BPS | 569 |
ChemSpider | 64783 |
UNII | 29PW75S82A |
ChEMBL | CHEMBL324665 |
ECHA InfoCard | 100.055.387 |
Chemical and physical data | |
Formula | C18H22N2O2 |
Molar mass | 298.38 |
3D model (Jmol) | Interactive image |
|
Carazolol is a high affinity antagonist/partial inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
References[edit]
- ^ Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. doi:10.1016/0024-3205(79)90102-4. PMID 41147.
External links[edit]
- Carazolol at the US National Library of Medicine Medical Subject Headings (MeSH)
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |